E

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018
E

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018
E

A look at NK cells – an interview with Dr Michael Cagliuri

A look at the history of NK cell development and where we're going in future with this IO approach

March 7, 2018
E

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016
E

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018
E

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018
E

Pathways to success targeting CD47-SIRPα

Insights from researchers in the CD47 niche - what do they really think?

February 20, 2018
E

A look at the controversial CD47-SIRPα landscape

A look at the players in controversial CD47-SIRPα landscape

February 15, 2018
E

Flying high with the controversial CD47-SIRPα pathway in cancer

A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space

February 7, 2018
E

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018
E

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018
E

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018
E

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018
E

The science behind the venetoclax clinical trial strategy

Where is the venetoclax BCL-2 program going in hematologic malignancies?

December 18, 2017
E

ASH17 masterclass with Dr John Leonard on lymphomas

An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17

December 14, 2017
E

ASH17 Will MURANO impact the CLL landscape?

As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?

December 13, 2017
E
Snow at GWCC

Commentary on ASH17 Day 2 in Atlanta

Commentary on Sunday at 2017 ASH annual meeting in Atlanta

December 10, 2017
E

ASH17 – Day 1 Highlights and Lowlights

A look at some of the sessions and learnings from the first day at ASH 2017

December 9, 2017
E

ASH17 CAR T cell therapy Preview

A look at what's hot in CAR T cell therapies at #ASH17

December 4, 2017
E

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017
E

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017
E

ASH17 Preview of emerging therapies for Aggressive Lymphomas

A look at up and coming emerging therapies in the DLBCL space

November 1, 2017